SHBG and polycystic ovary syndrome: The aim of this study was to evaluate the 3-month-long impact of VLCKD on AMH levels (ovarian reserve quality marker), progesterone levels on the 21st day of menstrual cycle (luteal phase adequacy marker), and SHBG levels (prognostic metabolic risk marker for type 2 diabetes mellitus (T2DM) development) in a cohort of obese non-diabetic women with PCOS and regular menstruation.